2014
Treatment of Hodgkin Lymphoma: A 50-Year Perspective
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita VT. Treatment of Hodgkin Lymphoma: A 50-Year Perspective. Journal Of Clinical Oncology 2014, 32: 163-168. PMID: 24441526, DOI: 10.1200/jco.2013.53.1194.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinClinical Trials as TopicCyclophosphamideDacarbazineDisease-Free SurvivalDoxorubicinEtoposideEuropeHistory, 20th CenturyHodgkin DiseaseHumansMechlorethamineNeoplasm StagingPositron-Emission TomographyPrednisoneProcarbazineSurvival RateTomography, X-Ray ComputedTreatment OutcomeVinblastineVincristine
2010
A breakthrough in Hodgkin's disease
DeVita V. A breakthrough in Hodgkin's disease. Nature Reviews Clinical Oncology 2010, 7: 179-179. PMID: 20354537, DOI: 10.1038/nrclinonc.2010.36.Peer-Reviewed Original Research
2008
The era of personalized medicine: back to basics
Hutchinson L, DeVita V. The era of personalized medicine: back to basics. Nature Reviews Clinical Oncology 2008, 5: 623-623. PMID: 18957968, DOI: 10.1038/ncponc1253.Peer-Reviewed Original ResearchAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBiomarkers, TumorCarcinoma, Non-Small-Cell LungCetuximabClinical Trials as TopicColorectal NeoplasmsDrug Delivery SystemsDrug Resistance, NeoplasmGene TargetingGenes, erbB-1HumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLung NeoplasmsPanitumumabPatient-Centered CarePiperazinesPyrimidinesTreatment Outcome
1988
On the value of response criteria in therapeutic research.
Devita V. On the value of response criteria in therapeutic research. Bulletin Du Cancer 1988, 75: 863-9. PMID: 3061500.Peer-Reviewed Original ResearchConceptsLocal tumor presentationPrimary chemotherapyTumor presentationBiological marker of responseResponse to primary chemotherapySmall-cell lung cancerDiffuse large-cell lymphomaResponse criteriaLarge-cell lymphomaComplete remission rateRelapse-free survivalFull dose chemotherapyPrimary tumor massMarkers of responseCytoreductive effectInduction chemotherapyDose chemotherapyRemission ratePediatric malignanciesTumor massPrimary treatmentChemotherapyLung cancerInduction cyclesAlternative therapies